Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

March 21, 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

March 21, 2024

Side effect profiles driven by fruquintinib use are discussed.

March 14, 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

March 14, 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

March 07, 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

March 07, 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

February 29, 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

February 29, 2024

Key safety considerations for the use of fruquintinib are explored.

February 22, 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

February 22, 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

July 13, 2023

Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.

April 21, 2023

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

April 14, 2023

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

April 11, 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

March 23, 2023

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

January 26, 2023

Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.

January 20, 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

January 18, 2023

Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.

December 22, 2022

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

September 12, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.